SonoVue (sulphur hexafluoride microbubbles) – contrast agent for contrast-enhanced ultrasound imaging of the liver

Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.

Last reviewed: 7 April 2016

We found nothing new that affects the recommendations in this guidance. For more information, see the review decision.

Diagnostics guidance 5 has been migrated to HealthTech guidance 291. The recommendations and accompanying content remain unchanged.

Next review: This guidance will be reviewed if there is new evidence that is likely to affect the recommendations.

Guidance development process

How we develop NICE HealthTech guidance